Long-Term JULIET Trial Data Shows CAR-T Therapy Delivers Durable Survival in Relapsed B-Cell Lymphoma
Key Insights
Final analysis of the foundational JULIET trial confirms tisagenlecleucel (Kymriah) provides long-term survival benefits for patients with relapsed or refractory large B-cell lymphoma (search), with five-year overall survival reaching 32%.
The study demonstrates CAR-T cells remain detectable in patient blood more than five years post-treatment, supporting the therapy's persistence and earning it the nickname "the living drug."
Historical survival projections for this patient population were under 5-10% at five years, making the 56% survival rate among responders a significant clinical breakthrough.
A landmark study published in the Journal of Clinical Oncology provides definitive evidence that tisagenlecleucel (Kymriah), one of the first FDA-approved CAR-T cell therapies, delivers long-term survival benefits and potential cures for adult patients with relapsed or refractory large B-cell lymphoma (search), even years after treatment.
The final analysis of the JULIET trial represents a significant milestone for CAR-T cell therapy (search), demonstrating that among 115 participants who received the treatment, the five-year overall survival rate reached approximately 32%, with an impressive 56% survival rate among patients who achieved a response to therapy.
Transforming Treatment Outcomes
"In a group where historical survival was projected to be under 5% to 10% at five years, we're now seeing clear evidence of long-term, durable remissions," said Richard Maziarz, M.D., former medical director of the adult blood and marrow stem cell transplant and current leader of the immune effector cellular therapy program at the OHSU Knight Cancer Institute. "We're not just talking about temporary responses anymore. We're talking about remission for more than five years in a disease that was once considered incurable at this stage."
The JULIET trial, launched around 2014, led to the approval of Novartis' chimeric antigen receptor therapy for adult patients with relapsed or refractory large B-cell lymphoma (search) who had failed at least two previous lines of systemic therapy. Oregon Health & Science University has been involved in the drug's clinical trials and subsequent FDA approval since 2014, with Maziarz serving as co-principal investigator alongside Stephen J. Schuster, M.D., of the University of Pennsylvania.
Persistence of "The Living Drug"
A particularly notable finding from the long-term analysis is that CAR-T cells remained detectable in the blood of some participants more than five years after treatment, supporting the therapy's long-term persistence and effectiveness. This persistence validates the appropriately coined nickname for CAR-T treatments as "the living drug."
Kymriah represents the first CAR-T cell gene therapy available in the U.S., utilizing a form of immunotherapy in which the patient's own blood cells are collected, genetically engineered to attack B-cell lymphoma cells (search), then infused back into the patient.
Expanding Treatment Landscape
The impact of the JULIET trial extends far beyond its original scope. "At the time of this original study, fewer than 100 people a year were getting CAR-T in the U.S. Now, it's approaching 6,000 annually," Maziarz noted. "This was the foundational study that helped make that growth possible."
The research has also identified key biological markers that could help predict which patients are most likely to benefit from CAR-T cell therapy (search). "It's not just about giving the drug anymore — it's about matching the right therapy to the right patient at the right time," Maziarz explained.
Future Directions and Access Challenges
Looking ahead, efforts are underway to move CAR-T cell therapy (search) even earlier in the treatment process, potentially into first-line care for high-risk disease. "We're exploring how to identify those at greatest risk of recurrence and intervene with CAR-T cell therapy before the disease becomes unmanageable," Maziarz said.
However, recent studies from Maziarz and colleagues highlight that access to these life-saving CAR-T cell therapies remains a challenge, particularly for lower-income and rural communities. "This isn't just about treating cancer anymore," he emphasized. "We've changed the natural history of the disease. And now the challenge is making sure everyone who needs this therapy can receive it."
The research was supported by industry partner Novartis, and represents what OHSU President Shereef Elnahal, M.D., M.B.A., described as "just one example of OHSU's long and growing history of exemplary cancer research and patient care."